Figure 2. Peritoneal delivery of immunomiR-carrying polyplexes in ovarian cancer patients elicits anti-tumor immunity.

Intraperitoneally-injected nanoparticles encapsulating synthetic miR-155 are preferentially taken-up by regulatory phagocytes at ovarian cancer locations. Non-specific activation of TLR5 and TLR7, combined with silencing of immunosuppressive targets of endogenous immunomiRs elicits the activation of tumor-associated regulatory dendritic cells, transforming them from an immunosuppressive to an immunostimulatory cell type. In situ activated dendritic cells promote the expansion and function of anti-tumor T cells by effectively presenting tumor antigens engulfed in the tumor microenvironment.